Caribou Biosciences is stopping work on its remaining allogeneic CAR-T programs after failing to secure financing for a late-stage trial in lymphoma. The company said it will pursue strategic alternatives, then move to wind down clinical development—bringing an end to a CRISPR-origin cell therapy effort after regulatory work on Phase 3 trial design.